Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products. Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA): Immunology research studies, including immunogenicity assessment of candidate biopharmaceutical products; Protein engineering to create humanized antibodies and deimmunised therapeutic proteins; Cell line development for the manufacture of recombinant proteins and antibodies; Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies; Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs); and Proprietary site-specific conjugation technologies and novel payloads for ADC development; and GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
AbZelect™ and AbZelectPRO™ support cell line development (CLD) to rapidly progress therapeutic protein and recombinant vaccine projects while de-risking the journey to Investigational New Drug (IND) application.
ThioBridge™ conjugation technology has been proven to enhance ADC development by overcoming issues with existing technologies in order to improve stability, potency, and efficacy.
EpiScreen® – an extensive suite of bioinformatic and primary human cell-based assays for immunogenicity assessment to inform of potential safety and efficacy risks in the clinic.
